1. Labcorp reports $3.53 billion revenue, up 9.5% from last year. 2. Raised 2025 guidance for revenue, adjusted EPS, and free cash flow. 3. Acquired assets from Incyte Diagnostics to enhance testing capabilities. 4. Launched innovative tests and digital health solutions in oncology and Alzheimer's. 5. Announced a quarterly cash dividend of $0.72 per share in September.
Labcorp's strong quarterly performance and guidance raise confidence among investors, akin to past strong earnings beats leading to price increases.
The raised guidance indicates robust business health and prospects, significantly impacting investor perception and stock valuations.
Immediate investor sentiment likely to be positive due to raised guidance and strong earnings, similar to previous patterns after good quarterly results.
BURLINGTON, N.C., July 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2025 and raised full-year guidance.
"Labcorp had a very strong second quarter, delivering double-digit topline growth, while expanding margins across both segments," said Adam Schechter, chairman and CEO of Labcorp. "We brought innovative tests to market, and applied our leadership in science and technology to drive growth, enhance the customer experience and improve our operations. We remain committed to delivering sustained value to our customers, employees and shareholders as we execute on our long-term strategy. Based upon our performance in the first half and our momentum going into the second half of the year, we're raising our guidance."
In the second quarter, Labcorp advanced its position as a partner of choice for hospitals, health systems and regional/local laboratories:
Three Months Ended June 30, 2025
Six Months Ended June 30, 2025
Labcorp is updating 2025 full year guidance to reflect its second quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of June 30, 2025, for the remainder of the year.
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and performed more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
This press release contains forward-looking statements regarding the company. Readers are cautioned not to place undue reliance on any of the forward-looking statements. Further information on potential factors, risks and uncertainties is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS.
For more information, please visit the investor relations section of the company's website.